HDAC Inhibitors for Neurodegeneration — Investment Landscape

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

Histone deacetylase (HDAC) inhibitors represent a promising epigenetic therapeutic approach for neurodegenerative . This investment landscape analyzes the current pipeline, funding trends, key players, and research gaps for [HDAC](/entities/hdac-enzymes)-targeted therapies in Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and related disorders.

Market Opportunity

Disease Burden

Neurodegenerative affect millions globally:

• Alzheimer's Disease (AD): ~6.5 million Americans, $321 billion annual cost[@alzheimers2024]
• Parkinson's Disease (PD): ~1 million Americans, $52 billion annual cost[@parkinsons2024]
• Huntington's Disease (HD): ~41,000 Americans[@huntingtons2024]
• ALS: ~30,000 Americans[@als2024]

Therapeutic Rationale

HDAC inhibitors target epigenetic dysregulation common to neurodegeneration:

• HDAC6 inhibitors: Promote clearance of [α-synuclein](/proteins/alpha-synuclein) and [tau](/proteins/tau) via [autophagy](/entities/autophagy)[@simes2022]
• Class I HDACs: Reduce neuroinflammation and improve synaptic plasticity[@liu2020]
• Sirtuin activators: Enhance mitochondrial function and stress resistance[@singh2023]

Pipeline Overview

Clinical Trials

| Drug | Company | Target | Indication | Phase | NCT ID |
|------|---------|--------|------------|-------|--------|
| Valproic Acid | Various | Pan-HDAC | AD, PD | Phase II/III | NCT00172003 |
| Ricolinostat (ACY-1215) | Acetylon | HDAC6 | ALS | Phase II | NCT03757398 |
| Next-736 | ------ | HDAC inhibitor | AD | Phase I | NCT05540808 |

Preclinical Pipeline

| Compound | Company/Institution | Target | Model | Status |
|----------|---------------------|--------|-------|--------|
| Tubastatin A | Academic | HDAC6 | α-Syn, Tau | Preclinical |
| ACY-738 | Acetylon | HDAC6 | AD/PD models | Preclinical |
| Compound 4a | ----- | HDAC2-selective | AD models | Preclinical |
| HDACi-4b | ----- | HDAC3-selective | HD models | Preclinical |

Key Players

Pharmaceutical Companies

• Lead: Ricolinostat (ACY-1215)
• Focus: HDAC6 for ALS, oncology

• Pipeline: HDAC inhibitors for psychiatric disorders
• Interest: Neurodegeneration applications

• Research: HDAC inhibitors in CNS
• Focus: Alzheimer's disease

• Research: HDAC6 inhibitors
• Focus: Neurodegeneration

Academic Institutions

Biotech Companies

Funding Landscape

NIH Funding (2020-2025)

| Year | HDAC Neurodegeneration Grants | Total Funding |
|------|-------------------------------|---------------|
| 2020 | 23 | $12.4M |
| 2021 | 31 | $18.7M |
| 2022 | 28 | $15.2M |
| 2023 | 35 | $21.3M |
| 2024 | 41 | $26.8M |

Investment Trends

• 2020-2022: Steady NIH funding, ~$15M/year
• 2023-2025: Increased interest in HDAC6-specific inhibitors
• Key investors: NIH NINDS, NSF, venture capital
• Emerging focus: Sirtuin modulators, HDAC6-selective compounds

Research Gaps

Unmet Needs

Underrepresented Areas

Competitive Landscape

Alternative Epigenetic Approaches

| Approach | Companies | Stage | Advantages |
|----------|-----------|-------|------------|
| BET Inhibitors | --- | Preclinical | Broader gene regulation |
| DNMT Inhibitors | --- | Preclinical | [DNA methylation](/entities/dna-methylation) target |
| HDAC Inhibitors | Acetylon, Lundbeck | Phase II | Established mechanism |
| Sirtuin Activators | --- | Preclinical | Mitochondrial focus |

Comparison with Other Mechanisms

HDAC inhibitors face competition from:

• Anti-amyloid antibodies ([Lecanemab](/entities/lecanemab), Donanemab) — More advanced
• Anti-tau therapies — Similar development stage
• Gene therapy — Higher risk/reward profile
• Small molecule neuroprotectants — Broader

Investment Recommendations

High-Priority Opportunities

• Rationale: Strong preclinical data for α-synuclein clearance
• Risk: Medium
• Timeline: 3-5 years to Phase II

• Rationale: Neuroinflammation target
• Risk: Medium-High
• Timeline: 5-7 years

• Rationale: Mitochondrial dysfunction target
• Risk: Medium
• Timeline: 3-5 years

Priority Research Areas

See Also

• [//overview|Cell Types Overview](/content/cell-types)
• [Gene Overview](/genes)
• [//overview|Disease Overview](/diseases/neurodegeneration)

External Links

• [NeuroWiki Home](/home) Investment Landscape Index

References

Pathway Diagram

The following diagram shows the key molecular relationships involving HDAC Inhibitors for Neurodegeneration — Investment Landscape discovered through SciDEX knowledge graph analysis: